1 research outputs found

    CYP1A1 Gene: A Cancer Risk Modifier

    Get PDF
    AbstractCYP1A1gene is an important target in cancer, due to its role in metabolic bioactivation of polycyclic aromatic hydrocarbons (PAHs),to electrophilic intermediates referred to bay region epoxides, to ultimate carcinogens and capable of causing oncogenic mutations in DNA. Expression of CYP1A1 mRNA is elevated by activation of the arylhydrocarbon receptor (AhR) through binding of exogenous ligands such as PAHs, of which the halogenated derivative 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is a prototype, then translocates from cytoplasm to nucleus upon the activation. Hence, disruption of these regulatory pathways is implicated in tumor progression. In addition, up-regulation of protein kinase C (PKC) and tyrosine kinase, as well as activation of mitogen-activated protein kinases (MAPKs) result in increase of AhR signal transduction. Glucocorticoid receptor (GR) and estrogen receptor (ER) also affect AhR-mediated pathway, but undergoing via different aspects Namely, GR decreases AhR-mediated expression by interacting with xenobiotic responsive element-binded AhR, while ER has a direct interaction with CYP1A1 promotor by acting as a co-regulator of AhR-mediated transcriptional activation. In normal condition, AhR plays a promoting role in cell cycle progression. In the existence of exogenous ligands, AhR shows inhibitory effect vice vesa . CYP1A1 is expressed constitutively in several extrahepatic tissues such as intestine, lung, placenta, and kidney, but not in liver. However, CYP1A1 expression has been demonstrated in the liver after inducer treatment. Therefore, cancer progression regarding overexpression of CYP1A1 possibly occurred in several organs related to exogenous ligands in every day exposures, e.g. smoking, diet, and the environment. Apart from these, genetic polymorphism of CYP1A1 gene has recently been noted to involve in difference types of cancer.Key words:CYP1A1 gene, aryl hydrocarbon receptor, cancer, AhR āļšāļ—āļ„āļąāļ”āļĒāđˆāļ­āļĒāļĩāļ™āđ„āļ‹āđ‚āļ•āđ‚āļ„āļĢāļĄ āļžāļĩ 450 1 āđ€āļ­ 1 (CYP1A1) āđ€āļ›āđ‡āļ™āļĒāļĩāļ™āđ€āļ›āđ‰āļēāļŦāļĄāļēāļĒāļŠāļģāļ„āļąāļāļŦāļ™āļķāđˆāļ‡āļ‚āļ­āļ‡āļĄāļ°āđ€āļĢāđ‡āļ‡ āđ€āļ™āļ·āđˆāļ­āļ‡āļˆāļēāļāļĄāļĩāļŦāļ™āđ‰āļēāļ—āļĩāđˆāļŦāļĨāļąāļāđƒāļ™āļāļēāļĢāđ€āļ›āļĨāļĩāđˆāļĒāļ™āđāļ›āļĨāļ‡āļ—āļēāļ‡āļŠāļĩāļ§āļ āļēāļžāļ‚āļ­āļ‡āļŠāļēāļĢāļāļĨāļļāđˆāļĄpolycyclic aromatic hydrocarbon (PAHs) āđƒāļŦāđ‰āļ­āļĒāļđāđˆāđƒāļ™āļĢāļđāļ›āļŠāļēāļĢāļāļķāđˆāļ‡āļāļĨāļēāļ‡āļˆāļģāļžāļ§āļepoxide āļŦāļĢāļ·āļ­āļŠāļēāļĢāļāđˆāļ­āļĄāļ°āđ€āļĢāđ‡āļ‡āļ—āļĩāđˆāļĄāļĩāļĪāļ—āļ˜āļīāļŠāđŒ āļđāļ‡āļŠāļļāļ”āļ‹āļķāđˆāļ‡āļŠāļēāļĄāļēāļĢāļ–āļāļĢāļ°āļ•āļļāđ‰āļ™āļāļĢāļ°āļšāļ§āļ™āļāļēāļĢāļāļĨāļēāļĒāļžāļąāļ™āļ˜āļļāđŒāđƒāļ™āļŠāļēāļĒāļ”āļĩāđ€āļ­āđ‡āļ™āđ€āļ­āļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡āļāļąāļšāļāļēāļĢāđ€āļāļīāļ”āļĄāļ°āđ€āļĢāđ‡āļ‡āđ„āļ”āđ‰ mRNA āļ‚āļ­āļ‡CYP1A1 āļˆāļ°āļ–āļđāļāđ€āļŦāļ™āļĩāđˆāļĒāļ§āļ™āļģāđƒāļŦāđ‰āđ€āļžāļīāđˆāļĄāļ‚āļķāđ‰āļ™āļ”āđ‰āļ§āļĒāļāļēāļĢāļāļĢāļ°āļ•āļļāđ‰āļ™āļāļēāļĢāļˆāļąāļšāļĢāļ°āļŦāļ§āđˆāļēāļ‡āļ•āļąāļ§āļĢāļąāļšaryl hydrocarbon (AhR) āļāļąāļš ligand)āđ„āļ”āđ‰āđāļāđˆ āļŠāļēāļĢ PAH āļ—āļĩāđˆāļĄāļĩāļ­āļ™āļļāļžāļąāļ™āļ˜āđŒāļ‚āļ­āļ‡2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) āđ€āļ›āđ‡āļ™āļŠāļēāļĢāļ•āđ‰āļ™āđāļšāļš āļˆāļēāļāļ™āļąāđ‰āļ™āļŠāļēāļĢāļ›āļĢāļ°āļāļ­āļšāļ‚āļ­āļ‡āļ•āļąāļ§āļĢāļąāļš AhR āđāļĨāļ° ligand āļˆāļ°āļœāđˆāļēāļ™āđ€āļ‚āđ‰āļēāļŠāļđāđˆāļ™āļīāļ§āđ€āļ„āļĨāļĩāļĒāļŠāļ­āļąāļ™āđ€āļ›āđ‡āļ™āļˆāļļāļ”āđ€āļĢāļīāđˆāļĄāļāļēāļĢāļāļĢāļ°āļ•āļļāđ‰āļ™āļĒāļĩāļ™ CYP1A1 āļ”āļąāļ‡āļ™āļąāđ‰āļ™āļāļēāļĢāļĢāļšāļāļ§āļ™āļāļĨāđ„āļāļāļēāļĢāļ„āļ§āļšāļ„āļļāļĄāđƒāļ” āđ† āļˆāļ°āļŠāđˆāļ‡āļœāļĨāļ•āđˆāļ­āļāļĢāļ°āļšāļ§āļ™āļāļēāļĢāđ€āļˆāļĢāļīāļāđ€āļ•āļīāļšāđ‚āļ•āļ‚āļ­āļ‡āđ€āļ‹āļĨāļĨāđŒāļĄāļ°āđ€āļĢāđ‡āļ‡ āļĒāļīāđˆāļ‡āđ„āļ›āļāļ§āđˆāļēāļ™āļĩāđ‰āļāļēāļĢāđ€āļžāļīāđˆāļĄāļāļēāļĢāļ—āļģāļ‡āļēāļ™āļ‚āļ­āļ‡ protein kinase C (PKC), tyrosine kinase āđāļĨāļ°āļāļēāļĢāļāļĢāļ°āļ•āļļāđ‰āļ™mitogen-activated protein kinases (MAPKs) āļˆāļ°āļŠāđˆāļ‡āļœāļĨāđƒāļŦāđ‰āđ€āļžāļīāđˆāļĄāļāļēāļĢāļŠāđˆāļ‡āļŠāļąāļāļāļēāļ“āļ‚āļ­āļ‡āļ•āļąāļ§āļĢāļąāļš AhR āļ™āļ­āļāļˆāļēāļāļ™āļĩāđ‰ glucocorticoid receptor (GR) āđāļĨāļ°estrogen receptor (ER) āļĒāļąāļ‡āđāļŠāļ”āļ‡āļœāļĨāļĢāđˆāļ§āļĄāļ•āđˆāļ­āļāļĢāļ°āļšāļ§āļ™āļāļēāļĢāļŠāđˆāļ‡āļŠāļąāļāļāļēāļ“āļ‚āļ­āļ‡āļ•āļąāļ§āļĢāļąāļš AhR āđ„āļ”āđ‰ āļ­āļēāļ—āļī GR āļŠāļēāļĄāļēāļĢāļ–āļĨāļ”āļāļēāļĢāđāļŠāļ”āļ‡āļ­āļ­āļāļ‚āļ­āļ‡āļĒāļĩāļ™ CYP1A1 āļ—āļĩāđˆāđāļŠāļ”āļ‡āļœāļĨāļœāđˆāļēāļ™āļāļĨāđ„āļāļ‚āļ­āļ‡āļ•āļąāļ§āļĢāļąāļš AhR āđ‚āļ”āļĒāļˆāļąāļšāļāļąāļšāļ­āļ‡āļ„āđŒāļ›āļĢāļ°āļāļ­āļšāļ‚āļ­āļ‡āļ•āļąāļ§āļĢāļąāļš AhRāļŦāļĢāļ·āļ­āļ­āļ‡āļ„āđŒāļ›āļĢāļ°āļāļ­āļšāļ āļēāļĒāđƒāļ™āļĒāļĩāļ™āļ—āļĩāđˆāļ•āļ­āļšāļŠāļ™āļ­āļ‡āļ•āđˆāļ­āļŠāļēāļĢāđāļ›āļĨāļāļ›āļĨāļ­āļĄ (xenobioticresponsive element) āđƒāļ™āļ‚āļ“āļ°āļ—āļĩāđˆ ER āļŠāļēāļĄāļēāļĢāļ–āļŠāđˆāļ‡āļœāļĨāđ‚āļ”āļĒāļ•āļĢāļ‡āļ•āđˆāļ­āļŠāđˆāļ§āļ™āđ‚āļ›āļĢāđ‚āļĄāđ€āļ•āļ­āļĢāđŒāļ āļēāļĒāđƒāļ™āļĒāļĩāļ™ CYP1A1 āđ‚āļ”āļĒāđ€āļ›āđ‡āļ™āđ€āļŠāļĄāļ·āļ­āļ™āļ•āļąāļ§āļ„āļ§āļšāļ„āļļāļĄāļĢāđˆāļ§āļĄāđƒāļ™āļāļēāļĢāđ€āļŦāļ™āļĩāđˆāļĒāļ§āļ™āļģāļœāđˆāļēāļ™āļ•āļąāļ§āļĢāļąāļš AhR āđƒāļ™āļŠāļ āļēāļ§āļ°āļ›āļāļ•āļīāļ•āļąāļ§āļĢāļąāļš AhR āļĄāļĩāļšāļ—āļšāļēāļ—āļŠāđˆāļ‡āđ€āļŠāļĢāļīāļĄāļāļēāļĢāđ€āļˆāļĢāļīāļāđ€āļ•āļīāļšāđ‚āļ•āļ‚āļ­āļ‡āđ€āļ‹āļĨāļĨāđŒāđāļ•āđˆāļ•āļąāļ§āļĢāļąāļš AhR āļŠāļēāļĄāļēāļĢāļ–āđāļŠāļ”āļ‡āļœāļĨāļ•āļĢāļ‡āļāļąāļ™āļ‚āđ‰āļēāļĄāđƒāļ™āļŠāļ āļēāļ§āļ°āļ—āļĩāđˆāļĄāļĩāļĨāļīāđāļāļ™āļ”āđŒ āđ€āļ™āļ·āđˆāļ­āļ‡āļˆāļēāļāļĒāļĩāļ™ CYP1A1 āļŠāļēāļĄāļēāļĢāļ–āļžāļšāđ„āļ”āđ‰āđƒāļ™āđ€āļ™āļ·āđ‰āļ­āđ€āļĒāļ·āđˆāļ­āļŦāļĨāļēāļĒāļŠāļ™āļīāļ”āđ€āļŠāđˆāļ™ āļ›āļ­āļ” āļĢāļ āļ•āļąāļšāđāļĨāļ°āđ„āļ• āđāļĄāđ‰āļ§āđˆāļēāļˆāļ°āļžāļšāļĒāļĩāļ™āļ™āļĩāđ‰āđƒāļ™āļ•āļąāļšāđ€āļĄāļ·āđˆāļ­āļ–āļđāļāđ€āļŦāļ™āļĩāđˆāļĒāļ§āļ™āļģāļ”āđ‰āļ§āļĒāļŠāļēāļĢāļāļĢāļ°āļ•āļļāđ‰āļ™āļ•āđˆāļēāļ‡ āļ”āļąāļ‡āļ™āļąāđ‰āļ™āļāļĢāļ°āļšāļ§āļ™āļāļēāļĢāđ€āļˆāļĢāļīāļāļ‚āļ­āļ‡āļĄāļ°āđ€āļĢāđ‡āļ‡āļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡āļāļąāļšāļāļēāļĢāđāļŠāļ”āļ‡āļ­āļ­āļāļ—āļĩāđˆāļĄāļēāļāđ€āļāļīāļ™āđ„āļ›āļ‚āļ­āļ‡āļĒāļĩāļ™ CYP1A1 āļˆāļķāļ‡āļĄāļĩāđ‚āļ­āļāļēāļŠāđ€āļāļīāļ”āļ‚āļķāđ‰āļ™āđƒāļ™āļ­āļ§āļąāļĒāļ§āļ°āļŦāļĨāļēāļĒāļŠāļ™āļīāļ”āļˆāļēāļāļāļēāļĢāđ„āļ”āđ‰āļĢāļąāļšāļĨāļīāđāļāļ™āļ”āđŒāļ āļēāļĒāļ™āļ­āļāļ—āļĩāđˆāļ›āļ™āđ€āļ›āļ·āđ‰āļ­āļ™āļ­āļĒāļđāđˆāļ—āļąāđˆāļ§āđ„āļ›āđƒāļ™āļŠāļ āļēāļ§āļ°āđāļ§āļ”āļĨāđ‰āļ­āļĄāļ™āļ­āļāļˆāļēāļāļ™āļĩāđ‰āļ„āļ§āļēāļĄāļŦāļĨāļēāļāļŦāļĨāļēāļĒāļ—āļēāļ‡āļžāļąāļ™āļ˜āļļāļāļĢāļĢāļĄāļ‚āļ­āļ‡āļĒāļĩāļ™ CYP1A1 āļžāļšāļ§āđˆāļēāļŠāļąāļĄāļžāļąāļ™āļ˜āđŒāļāļąāļšāđ‚āļ­āļāļēāļŠāđ€āļāļīāļ”āļĄāļ°āđ€āļĢāđ‡āļ‡āļŦāļĨāļēāļĒāļ›āļĢāļ°āđ€āļ āļ—āļ”āđ‰āļ§āļĒāļ„āļģāļŠāļģāļ„āļąāļ: āļĒāļĩāļ™āđ„āļ‹āđ‚āļ•āđ‚āļ„āļĢāļĄ āļžāļĩ 450 1 āđ€āļ­ 1, āļ•āļąāļ§āļĢāļąāļšāđāļ­āļĢāļīāļĨāđ„āļŪāđ‚āļ”āļĢāļ„āļēāļĢāđŒāļšāļ­āļ™,āļĄāļ°āđ€āļĢāđ‡āļ‡, AhR
    corecore